Masoumeh Beig

Masoumeh Beig

Auto-generated profile, based on publicly available information

Masoumeh Beig

Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran; Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2025 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
CHChou-Yi Hsu
Chou-Yi Hsu
SMSafoura Moradkasani
Safoura Moradkasani
MSMuath Suliman
Muath Suliman
SUSubasini Uthirapathy
Subasini Uthirapathy
AZAhmed Hussein Zwamel
Ahmed Hussein Zwamel
MBMasoumeh Beig
Masoumeh Beig
Objectives: Streptococcus agalactiae, or group B Streptococcus (GBS), is a significant pathogen associated with severe infections in neonates, particularly sepsis and meningitis. The increasing prevalence of antibiotic resistance among GBS strains is a growing public health concern, necessitating a comprehensive meta-analysis to evaluate the prevalence of this resistance globally.Methods: We conducted a comprehensive systematic search across four major scientific databases: Scopus, PubMed, Web of Science, and EMBASE, targeting articles published until December 13, 2023. This meta-analysis focused on studies that examined antibiotic resistance in GBS strains. The Joanna Briggs Institute tool was employed to assess the quality of the included studies. This meta-analysis applied a random-effects model to synthesize data on antibiotic resistance in GBS, incorporating subgroup analyses and regression techniques to explore heterogeneity and trends in resistance rates over time. Outliers and influential studies were identified using statistical methods such as Cook’s distance, and funnel plot asymmetry was assessed to evaluate potential publication bias. All analyses were conducted using R software (version 4.2.1) and the metafor package (version 3.8.1).Results: This study included 266 studies from 57 countries, revealing significant variability in GBS antibiotic resistance rates. The highest resistance rates were observed for tetracycline (80.1, 95% CI: 77.1–82.8%), while tedizolid (0.1, 95% CI: 0.0–0.8%) showed the lowest resistance rates. Significant heterogeneity in resistance rates was observed, particularly for antibiotics such as azithromycin and gentamicin (I2 = 97.29%), variability across studies. On the other hand, tigecycline and ceftaroline exhibited no heterogeneity (I2 = 0%), suggesting consistent resistance patterns. Subgroup analyses revealed disparities in resistance rates based on country, continent, and methodological categories. Significant increase in resistance rates for several antibiotics over time, including clindamycin, erythromycin, ceftriaxone, cefuroxime, ciprofloxacin, levofloxacin, moxifloxacin, chloramphenicol, and ofloxacin. Ofloxacin and cefuroxime showed particularly steep trends. Conversely, a declining resistance trend was observed for oxacillin.Conclusion: This study emphasizes the growing issue of antibiotic resistance in GBS strains. Notable resistance to older and newer antibiotics, increasing resistance over time, regional disparities, and methodological variations are noted. Rising resistance trends for multiple antibiotics underscore the urgent need for global surveillance and improved antibiotic stewardship.Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024566269, CRD42024566269.

14 March 2025 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
TNTahereh Navidifar
Tahereh Navidifar
ABAbbas Zare Banadkouki
Abbas Zare Banadkouki
EPElnaz Parvizi
Elnaz Parvizi
MMMaryam Mofid
Maryam Mofid
NGNarges Golab
Narges Golab
MSMohammad Sholeh
Mohammad Sholeh
Background: Staphylococcus is a genus of bacteria responsible for various infections ranging from mild skin to severe systemic diseases. Methicillin-resistant Staphylococcus aureus (MRSA) and coagulase-negative staphylococci (CoNS) are significant challenges owing to their resistance to multiple antibiotics, including macrolides, such as erythromycin, clarithromycin, and azithromycin.Objective: This study aimed to systematically review and synthesize data on the prevalence of macrolide resistance in Staphylococcus spp., identify trends and changes in resistance patterns over time, and assess how testing methods and guidelines affect reported resistance rates.Methods: The study conducted a systematic search of the Scopus, PubMed, Web of Science, and EMBASE databases. Studies have reported the proportion of macrolide-resistant Staphylococcus spp. Two authors independently extracted and analyzed the data using a random-effects model. Heterogeneity was assessed, and subgroup analyses were performed based on country, continent, species, AST guidelines, methods, and period.Results: In total, 223 studies from 76 countries were included. The pooled prevalence of resistance to erythromycin, clarithromycin, and azithromycin were 57.3, 52.6, and 57.9%, respectively. Significant heterogeneity was observed across studies (I2 > 95%, p < 0.001). Oceania (72%) had the highest erythromycin resistance, whereas Europe had the lowest (40.7%). Subgroup analyses revealed variations in resistance based on the species, with higher resistance in MRSA than in MSSA and CoNS than in other species. Over time, a slight decrease in erythromycin resistance has been observed (59.6% from 2015–2019 to 55% from 2020–2023).Conclusion: This study emphasizes the high prevalence of macrolide resistance in Staphylococcus spp. and its notable regional variation. These findings highlight the necessity for standardized methodologies and global surveillance to manage macrolide resistance effectively. Controlling antibiotic resistance should prioritize enhancing public health measures and updating treatment guidelines.Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=557756, CRD42024557756.

30 October 2024 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
SKSafoura Morad Kasani
Safoura Morad Kasani
MMMaryam Mofid
Maryam Mofid
TNTahereh Navidifar
Tahereh Navidifar
NGNarges Golab
Narges Golab
EPElnaz Parvizi
Elnaz Parvizi
MBMasoumeh Beig
Masoumeh Beig
Background: Helicobacter pylori infection is a primary global health concern. However, the widespread use of antibiotics, particularly macrolides such as clarithromycin, has increased resistance among H. pylori strains. This study aimed to investigate the prevalence of macrolide resistance in H. pylori in different world regions.Methods: This systematic literature search was performed using the appropriate search syntax after searching PubMed, Embase, Web of Science, and Scopus databases between May 2015 and December 2023. Statistical analysis was performed using Pooled and random effects model in R and the metafor package.Results: A total of 7,768 articles were retrieved. After a thorough evaluation, 155 studies (by 178 reports) were finally eligible for inclusion in this systematic review and meta-analysis. According to the results, the majority of studies (178 reports from 43 countries) assessed clarithromycin susceptibility, with a pooled prevalence of 33.3% and high heterogeneity between studies (I2 = 98.57%, p < 0.001). The rate of erythromycin resistance was moderate (22.8%, 10 reports), while azithromycin resistance was 34.4% (4 reports). Subgroup analysis revealed significant differences in the prevalence of resistance based on geographic location, continent, and year of publication. Clarithromycin resistance increased from 29.1% (2015–2019) to 36.5% (2020–2023).Conclusion: This study highlights the critical challenges of macrolide resistance in treating H. pylori infection. The high prevalence and geographic variation underscore the need for tailored treatment strategies based on regional resistance patterns. Furthermore, continuously monitoring resistance trends and investigating contributing factors are essential to optimize treatment.Systematic review registration: https://www.crd.york.ac.uk/prospero; CRD42024557749.

1 January 2024 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
MAmarzie mahdizade ari
marzie mahdizade ari
MBMasoumeh Beig
Masoumeh Beig
MSMohammad Sholeh
Mohammad Sholeh
MKMajid Khoshmirsafa
Majid Khoshmirsafa
Ari MM, et al. Clin Exp Vaccine Res. 2024 Jul;13(3):184-201. https://doi.org/10.7774/cevr.2024.13.3.184

14 November 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
Ali ShivaeeAli Shivaee
Ali Shivaee
FKFatemeh Kazemi
Fatemeh Kazemi
TNTahereh Navidifar
Tahereh Navidifar
NGNarges Golab
Narges Golab
EPElnaz Parvizi
Elnaz Parvizi
MBMasoumeh Beig
Masoumeh Beig
The widespread use of macrolides and lincosamides, particularly for treating infections caused by Streptococcus pyogenes (S. pyogenes) (group A Streptococcus (GAS)), and S. pneumoniae has led to a concerning rise in antibiotic resistance. This meta-analysis aimed to evaluate the weighted pooled resistance rates of macrolides and lincosamides in clinical isolates of S. pneumoniae, S. pyogenes, and S. agalactiae (group B Streptococcus (GBS)) based on time, geographical areas, antimicrobial susceptibility testing, and guidelines. We systematically searched PubMed, Embase, Web of Science, and Scopus for studies published between 2015 and 2023. Study quality was assessed via the Joanna Briggs Institute Checklist. Resistance rates were calculated with a random-effects model, supplemented by meta-regression, subgroup analyses, and identification of outliers. Statistical analyses were performed in R using the metafor package. This review analyzed 276 studies across 62 countries. Pooled resistance was highest for clarithromycin (57.6%) and azithromycin (55.8%), followed by erythromycin (41.5%) and clindamycin (29.5%), all with substantial heterogeneity (I2 > 98%, p < 0.001). Resistance differed significantly across various countries and continents (p < 0.001). Resistance patterns varied notably by species, with S. pneumoniae exhibiting the highest resistance to all tested macrolides and lincosamides, followed closely by S. agalactiae. In contrast, S. pyogenes consistently showed the lowest resistance levels across all antibiotics examined. A significant upward trend in resistance was observed over time for erythromycin (p = 0.019) and clindamycin (p = 0.003). According to the meta-regression, the erythromycin resistance rate increased over time (r = 0.094, p = 0.005). Macrolide and lincosamide resistance among key Streptococcus species are alarmingly high and rising globally, with marked species-specific and regional differences. Our findings underscore the urgent need for standardized susceptibility testing protocols, targeted surveillance by species, and enhanced antibiotic stewardship efforts.

16 July 2021 in International Journal of Microbiology
Verified
Journal Article
Open access
PDF file
MBMasoumeh Beig
Masoumeh Beig
MTMohammad Taheri
Mohammad Taheri
MAMohammad Arabestani
Mohammad Arabestani
In recent years, the prevalence of carbapenem-resistant Pseudomonas aeruginosa isolates has become a worldwide concern. Rapid and accurate detection of carbapenemase-producing P. aeruginosa isolates is so important. The aim of this study was to evaluate the performance of the phenotypic methods such as Modified Hodge test (MHT), CarbaNP (CNPt), combined double-disk synergy test (CDDT), and carbapenem inactivation method (CIM) for rapid and accurate detection of clinical carbapenemase production of P. aeruginosa isolates. This study was performed on 97 P. aeruginosa strains, which were isolated from clinical samples in Hamadan hospitals, western Iran in 2017-2018. Antibiotic susceptibility testing was performed using disk diffusion and minimum inhibitory concentration (MIC) by E-test method. We evaluated the performance of MHT, CarbaNP, CDDT, and CIM tests in comparison to polymerase chain reaction (PCR) for the detection of carbapenemase-producing isolates. Additionally, the presence of carbapenem-resistant genes was investigated using the PCR method. Our findings showed that the highest resistance was to cefoxitin (94.8). Moreover, among the carbapenem antibiotics, the highest resistance was to imipenem (49.4). Among the 49 carbapenem-resistant isolates, 42 (85.7) isolates were MIC positive. The results of phenotypic tests showed that CarbaNP, CIM, CDDT, and MHT tests were positive in (48/49, 97.95), (46/49, 93.87), (27/49, 57.44), and (25/49, 53.19) of isolates, respectively. CarbaNP and CIM tests showed high sensitivity, specificity, positive predictive values (PPV), and negative predictive values (NPV) compared to PCR in P. aeruginosa isolates. CarbaNP and CIM tests are highly sensitive and specific tests for identifying carbapenemase-producing P. aeruginosa isolates.